Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia.

Trial Profile

A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary) ; Aripiprazole (Primary) ; Paliperidone; Paliperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms QUALIFY
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 01 Mar 2017 Resultsb of a post-hoc analysis evaluating the differential treatment effects of Aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate (PP) on sexual dysfunction and prolactin levels, published in the International Clinical Psychopharmacology.
    • 08 Dec 2016 Results published in the International Journal of Neuropsychopharmacology.
    • 20 Sep 2016 Results of a post-hoc analysis assessing effect sizes of aripiprazole and paliperidone palmitate in the treatment of schizophrenia, presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top